Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Leggat

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Advances in Renal Replacement Therapy|January 1, 1997
Withdrawal from dialysis: a review with an emphasis on the black experienceJ E Leggat, R D Swartz, F K Port
Journal of the American Society of Nephrology : JASN|November 14, 1997
An analysis of risk factors for withdrawal from dialysis before deathJ E Leggat, W E Bloembergen, G Levine, et al.
Transplantation Proceedings|June 21, 2007
Impact of recipient obesity on living donor kidney transplant outcomes: a single-center experienceR Mehta, G Shah, J E Leggat, et al.
Transplantation|March 1, 1989
Decrease in phenotypically defined T helper inducer cells (T4+4B4+) and increase in T suppressor effector cells (T8+2H4+) in stable renal allograft recipientsE L Ramos, L A Turka, J E Leggat, et al.
Human Immunology|December 1, 1987
Antigen specificity of mixed lymphocyte response-induced suppressor cellsL A Turka, E L Ramos, J E Leggat, et al.
Transplantation|May 15, 1997
Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodesJ E Leggat, A O Ojo, A B Leichtman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 21, 1998
Noncompliance in hemodialysis: predictors and survival analysisJ E Leggat, S M Orzol, T E Hulbert-Shearon, et al.
Transactions of the Association of American Physicians|January 1, 1989
In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenicE L Ramos, J E Leggat, E L Milford, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Advances in Renal Replacement Therapy|January 1, 1997
Withdrawal from dialysis: a review with an emphasis on the black experienceJ E Leggat, R D Swartz, F K Port
Journal of the American Society of Nephrology : JASN|November 14, 1997
An analysis of risk factors for withdrawal from dialysis before deathJ E Leggat, W E Bloembergen, G Levine, et al.
Transplantation Proceedings|June 21, 2007
Impact of recipient obesity on living donor kidney transplant outcomes: a single-center experienceR Mehta, G Shah, J E Leggat, et al.
Transplantation|March 1, 1989
Decrease in phenotypically defined T helper inducer cells (T4+4B4+) and increase in T suppressor effector cells (T8+2H4+) in stable renal allograft recipientsE L Ramos, L A Turka, J E Leggat, et al.
Human Immunology|December 1, 1987
Antigen specificity of mixed lymphocyte response-induced suppressor cellsL A Turka, E L Ramos, J E Leggat, et al.
Transplantation|May 15, 1997
Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodesJ E Leggat, A O Ojo, A B Leichtman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 21, 1998
Noncompliance in hemodialysis: predictors and survival analysisJ E Leggat, S M Orzol, T E Hulbert-Shearon, et al.
Transactions of the Association of American Physicians|January 1, 1989
In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenicE L Ramos, J E Leggat, E L Milford, et al.
Pageof 1